Literature DB >> 2201750

Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.

A Podda1, L Nencioni, M T De Magistris, A Di Tommaso, P Bossù, S Nuti, P Pileri, S Peppoloni, M Bugnoli, P Ruggiero.   

Abstract

PT-9K/129G, a nontoxic mutant of pertussis toxin (PT) obtained by genetic manipulation, has been shown in animal models to be a promising candidate for new vaccines against whooping cough. To assess the safety and the immunogenicity of PT-9K/129G in humans, a pilot study has been performed in adult volunteers. The protein was found to be safe, capable of inducing high titers of toxin-neutralizing antibodies, and capable of generating immunological memory. In fact, vaccination caused an increase of cell-mediated response to PT, PT-9K/129G, S1 subunit, and B oligomer, indicating that memory T cells are induced by the vaccine. Since PT-9K/129G is mitogenic for T lymphocytes in vitro, it was investigated whether this activity is also present in vivo. No variation was observed in the proportion of T cells (CD3+), T helper cells (CD4+), and cytotoxic T cells (CD8+), as well as in that of other lymphoid populations, by FACS analysis. Interestingly, no thorough correlation was found between humoral and cellular responses. In one case, a very high cellular response was present in absence of detectable antibodies, suggesting that the antibody response, which is the only parameter measured in most clinical trials, may not give a complete picture of the response induced by a vaccine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201750      PMCID: PMC2188543          DOI: 10.1084/jem.172.3.861

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  Pertussis: epidemiology and control.

Authors:  A S Muller; J Leeuwenburg; D S Pratt
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

2.  Expression and immunological properties of the five subunits of pertussis toxin.

Authors:  A Nicosia; A Bartoloni; M Perugini; R Rappuoli
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

3.  Development of a pertussis component vaccine in Japan.

Authors:  Y Sato; M Kimura; H Fukumi
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

4.  Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase.

Authors:  R D Sekura; F Fish; C R Manclark; B Meade; Y L Zhang
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

5.  Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin.

Authors:  E L Hewlett; K T Sauer; G A Myers; J L Cowell; R L Guerrant
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

Review 6.  The concept of pertussis as a toxin-mediated disease.

Authors:  M Pittman
Journal:  Pediatr Infect Dis       Date:  1984 Sep-Oct

7.  Pertussis immunisation and serious acute neurological illness in children.

Authors:  D L Miller; E M Ross; R Alderslade; M H Bellman; N S Rawson
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-16

8.  Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.

Authors:  H Sato; Y Sato
Journal:  Dev Biol Stand       Date:  1985

9.  T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells.

Authors:  B Fleischer; H Schrezenmeier
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

10.  Dissecting human T cell responses against Bordetella species.

Authors:  M T De Magistris; M Romano; S Nuti; R Rappuoli; A Tagliabue
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  22 in total

1.  Generation of human monoclonal antibodies that confer protection against pertussis toxin.

Authors:  M Zaccolo; S Roggero; D Armellini; L Pegoraro; R Rappuoli; F Malavasi
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.

Authors:  I Marsili; M Pizza; F Giovannoni; G Volpini; M Bartalini; R Olivieri; R Rappuoli; L Nencioni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Properties of the B oligomer of pertussis toxin.

Authors:  L Nencioni; M G Pizza; G Volpini; M T De Magistris; F Giovannoni; R Rappuoli
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

5.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

6.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis.

Authors:  S Peppoloni; L Nencioni; A Di Tommaso; A Tagliabue; P Parronchi; S Romagnani; R Rappuoli; M T De Magistris
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

8.  Identification of human T-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  J W Petersen; A Holm; P H Ibsen; K Hasløv; C Capiau; I Heron
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

9.  Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.

Authors:  G Kanra; M Ceyhan; D Vandevoorde; H Bogaerts
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

10.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.